BOSTON--(BUSINESS WIRE)--Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage therapeutics company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that members of its management team will present at the 2025 RBC Capital Markets Healthcare Private Company Virtual Conference on Thursday, December 11, 2025 at 10:00 AM EST. The Company will also participate in one-on-one meetings during the conference.
The live and archived webcast of the presentation will be available under the Events section of the Seaport website at https://seaporttx.com/news-papers/.
About Seaport Therapeutics
Seaport Therapeutics is a clinical-stage therapeutics company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and is guided by an extensive network of renowned scientists, clinicians, and key opinion leaders. For more information, please visit www.seaporttx.com.
Contacts
Seaport Therapeutics
Public Relations
publicrelations@seaporttx.com
Investor Relations
ir@seaporttx.com
